Effects of eszopiclone on sleep quality and cognitive function in elderly patients with Alzheimer's disease and sleep disorder: A randomized controlled trial

Abstract

Objective: To investigate the effects of eszopiclone on sleep quality and cognitive function in elderly patients with Alzheimer's disease (AD) and sleep disorders. Methods:This study was a prospective study of 96 elderly patients with AD and sleep disturbance treated in our hospital from April 2019 to December 2020. All patients were divided into a control group (48 patients, given alprazolam tablets) and a study group (48 patients, given eszopiclone) according to the random number table method.Results: After treatment, compared with the control group, the study group had lower sleep latency, daytime function, sleep disturbance, sleep efficiency, sleep quality, sleeping time, and hypnotic medication scores (p < .05). After treatment, sleep progression and sleep architecture improvement were more obvious in the study group compared with the control group (p < .05). After treatment, compared with the control group, the rhythm disturbance, psychotic disorder, hallucination, phobic anxiety, and disorder in the study group improved more significantly (p < .05). After treatment, compared with the control group, the scores of orientation, attention, memory, calculation, recall, and language ability in the study group improved more significantly (p < .05). After treatment, the scores of the physical life self-care scale and instrumental activities of daily living scale in the study group were improved more obviously compared with the control group, with significant differences (p < .05). Conclusion:Eszopiclone can effectively improve the quality of sleep and cognitive function in elderly patients with AD and sleep disorder.

Circadian disruption and sleep disorders in neurodegeneration

“…A 6-week randomized controlled trial showed that eszoplicone significantly reduces the number of awakenings after sleep onset and improves subjective sleep quality in PD patients [ 218 ]. Similar results have been obtained in AD patients [ 219 ]. In fact, current evidence for clonazepam is mainly based on case reports and observational studies [ 220 , 221 ], thus more clinical trials are needed.…”

Mapping new pharmacological interventions for cognitive function in Alzheimer’s disease: a systematic review of randomized clinical trials

“…Benzodiazepines and related drugs have been associated with an increased risk of AD in old age and adverse events in patients with mild to moderate AD ( Dyer et al, 2020 ). Eszopiclone may improve sleep quality and cognitive function in elderly patients with AD and sleep disorders ( Huo et al, 2022 ). The combination of various treatments has a better effect than the use of a single treatment or monotherapy in patients with AD, both in moderate and severe stages ( Glinz et al, 2019 ; Guo et al, 2020 ; Knorz and Quante, 2022 ).…”

Effects of tranquilization therapy in elderly patients suffering from chronic non-communicable diseases: A meta-analysis

“…All included papers followed the PRISMA principles, and studies were chosen at random, regardless of language, publication status, or study type (prospective, retrospective, clinical trial). Patient demographics and event data from the included studies (16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31) were gathered and tallied.…”

“…A total of 2,224 senior individuals are there in the selected studies (16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31). The age of the patients included in the research spans from 45 to 75 years, with 64 % of males and 36 % of females.…”